Amgen’s Phase II MariTide Data Lack Clarity Market Hoped For
Efficacy, Safety Data Pooled, Limited
Much anticipated Phase II results in obesity for Amgen’s GLP-1 agonist/GIP antagonist showed up to 20% weight loss, but without detailed data the drug’s competitiveness is hard to ascertain.
